Reflecting on the key themes of #IMS2026 - >5 yr remission for newly diagnosed and >3 yrs in relapse for most MM is becoming the standard - High Risk MM is still a challenge, immunotherapy is key. Paucity of data in EMD and PCL. Agree with @VincentRK in adding PCL to HR definition -Access is key- after meeting with several drug manufacturers, this is being thought of in the design, clinical trial, execution both for CART and BsAb. Can every patient get this within 60 miles of their home. - TRM is more important esp. in the first 6 months -Less is more- Newer CART's have lesser CRS, ICANS and newer BsAb's have less intense dosing schedule with lower CRS -Dual Ag targeting is A way forward, a/w how it compares against good single agent targets -There is a paucity and some progress in understanding rare toxicities- Colitis, cerebellar syndromes, oral toxicities, rare infections -if we are going to give subsequent immunotherapies, we need to be more precise, with sequencing and T cell fitness, both of which are still in its infancy in MM -Except celmods there are no other non targeted therapies [non BCMA, GPRC5, FCRH5]. Is this enough ? [I am aware of others but none in Ph 3] -Cure - covered by @Mohty_EBMT already Thx for the organizers @profghjackson @NikhilMunshiMD @NoopurRajeMD @IMFmyeloma for a wonderful meeting and looking forward to next year